Last reviewed · How we verify
Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir
Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir is a Antiretroviral agents (INSTI, NNRTI, NRTI/NtRTI) Small molecule drug developed by St Stephens Aids Trust. It is currently FDA-approved for HIV-1 infection (treatment and prevention), AIDS. Also known as: Tivicay®, efavirenz, Atripla®.
These are antiretroviral drugs that inhibit HIV replication through different mechanisms: dolutegravir blocks integrase, efavirenz inhibits reverse transcriptase, and the combination tablet inhibits both reverse transcriptase and blocks viral entry.
These are antiretroviral drugs that inhibit HIV replication through different mechanisms: dolutegravir blocks integrase, efavirenz inhibits reverse transcriptase, and the combination tablet inhibits both reverse transcriptase and blocks viral entry. Used for HIV-1 infection (treatment and prevention), AIDS.
At a glance
| Generic name | Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir |
|---|---|
| Also known as | Tivicay®, efavirenz, Atripla® |
| Sponsor | St Stephens Aids Trust |
| Drug class | Antiretroviral agents (INSTI, NNRTI, NRTI/NtRTI) |
| Target | HIV integrase (dolutegravir); HIV reverse transcriptase (efavirenz and combination); HIV entry (tenofovir/emtricitabine component) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Dolutegravir is an integrase strand transfer inhibitor (INSTI) that prevents HIV from integrating its genetic material into human DNA. Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks the enzyme HIV uses to replicate. The combination tablet (efavirenz/emtricitabine/tenofovir) provides triple therapy with a reverse transcriptase inhibitor and two nucleoside/nucleotide reverse transcriptase inhibitors, suppressing viral replication through multiple pathways.
Approved indications
- HIV-1 infection (treatment and prevention)
- AIDS
Common side effects
- Diarrhea
- Nausea
- Headache
- Dizziness (efavirenz)
- Rash
- Elevated liver enzymes
- Neuropsychiatric effects (efavirenz)
- Renal impairment (tenofovir)
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
- Research on the Psychological Status of Patients With HIV-1 Infection
- Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen (PHASE2, PHASE3)
- Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir CI brief — competitive landscape report
- Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir updates RSS · CI watch RSS
- St Stephens Aids Trust portfolio CI
Frequently asked questions about Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir
What is Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir?
How does Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir work?
What is Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir used for?
Who makes Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir?
Is Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir also known as anything else?
What drug class is Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir in?
What development phase is Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir in?
What are the side effects of Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir?
What does Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir target?
Related
- Drug class: All Antiretroviral agents (INSTI, NNRTI, NRTI/NtRTI) drugs
- Target: All drugs targeting HIV integrase (dolutegravir); HIV reverse transcriptase (efavirenz and combination); HIV entry (tenofovir/emtricitabine component)
- Manufacturer: St Stephens Aids Trust — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection (treatment and prevention)
- Indication: Drugs for AIDS
- Also known as: Tivicay®, efavirenz, Atripla®
- Compare: Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir vs similar drugs
- Pricing: Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir cost, discount & access